

Reference:	FOI.7142.21
Subject:	Dermatological and rheumatological conditions
Date of Request:	11 October 2021

Requested:

- How many patients were treated in September 2021 (or latest available month) by the dermatology department with the following drugs:
 - Abrocitinib (Cibinqo)
 - Baricitinib (Olumiant)
 - Bimekizumab (Bimzelx)
 - Brodalumab (Kyntheum)
 - Dupilumab (Dupixent)
 - Ixekizumab (Taltz)
 - Risankizumab (Skyrizi)
 - Guselkumab (Tremfya)
 - Secukinumab (Cosentyx)
 - Tildrakizumab (Ilumetri)
 - Tralokinumab (Adtralza)
 - Ustekinumab (Stelara)
- How many patients were treated in September 2021 (or latest available month) by the rheumatology department with the following drugs:
 - Baricitinib (Olumiant)
 - Filgotinib (Jyseleca)
 - Guselkumab (Tremfya)
 - Ixekizumab (Taltz)
 - Secukinumab (Cosentyx)
 - Tofacitinib (Xeljanz)
 - Upadacitinib (Rinvoq)
 - Ustekinumab (Stelara)

Response:

- Hywel Dda University Health Board (UHB) provides, within the table below, the number of patients treated by the Dermatology Department with the listed medications, during September 2021.

Medication	Number
Abrocitinib (Cibinqo)	0
Baricitinib (Olumiant)	0
Bimekizumab (Bimzelx)	0
Brodalumab (Kyntheum)	0
Dupilumab (Dupixent)	19
Ixekizumab (Taltz)	*
Risankizumab (Skyrizi)	0
Guselkumab (Tremfya)	0

Secukinumab (Cosentyx)	8
Tildrakizumab (Ilumetri)	0
Tralokinumab (Adtralza)	0
Ustekinumab (Stelara)	12

2. The UHB provides, within the table below, the number of patients treated by the Rheumatology Department with the listed medications, during September 2021

Medication	Number
Baricitinib (Olumiant)	47
Filgotinib (Jyseleca)	5
Guselkumab (Tremfya)	0
Ixekizumab (Taltz)	*
Secukinumab (Cosentyx)	22
Tofacitinib (Xeljanz)	0
Upadacitinib (Rinvoq)	0
Ustekinumab (Stelara)	*

Where the figures in the tables have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients, due to the low numbers of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018/General Data Protection Regulations 2016 (GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/General Data Protection Regulations 2016 define personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.